These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29360915)

  • 1. The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.
    Barzilay JI; Davis BR; Pressel SL; Ghosh A; Rahman M; Einhorn PT; Cushman WC; Whelton PK; Wright JT
    Am J Hypertens; 2018 Apr; 31(5):609-614. PubMed ID: 29360915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
    Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
    Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
    Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of change in renal function and mortality in elderly treated hypertensive patients.
    Chowdhury EK; Langham RG; Ademi Z; Owen A; Krum H; Wing LM; Nelson MR; Reid CM;
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1154-61. PubMed ID: 25901093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
    Zhang X; Lynch AI; Davis BR; Ford CE; Boerwinkle E; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    PLoS One; 2012; 7(3):e34217. PubMed ID: 22470539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans.
    Gosmanova EO; Molnar MZ; Alrifai A; Lu JL; Streja E; Cushman WC; Kalantar-Zadeh K; Kovesdy CP
    Am J Nephrol; 2015; 42(2):151-7. PubMed ID: 26398170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
    Khayyat-Kholghi M; Oparil S; Davis BR; Tereshchenko LG
    JACC Heart Fail; 2021 Feb; 9(2):100-111. PubMed ID: 33189627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of the Estimated Glomerular Filtration Rate Decline in Hypertensive Patients Without Chronic Kidney Disease.
    Coll-de-Tuero G; Comas-Cufí M; Rodríguez-Poncelas A; Barrot-de-la Puente J; Blanch J; Figa-Vaello J; Barceló MA; Saez M
    Am J Hypertens; 2019 Aug; 32(9):890-899. PubMed ID: 30794282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
    Whittle J; Lynch AI; Tanner RM; Simpson LM; Davis BR; Rahman M; Whelton PK; Oparil S; Muntner P
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):471-80. PubMed ID: 26912544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Simpson LM; Ghosh A; Einhorn PT; Ford CE; Probstfield JL; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2018 Aug; 110(4):343-351. PubMed ID: 30126559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
    Moes AD; Hesselink DA; van den Meiracker AH; Zietse R; Hoorn EJ
    Am J Kidney Dis; 2017 Jun; 69(6):796-804. PubMed ID: 28259499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
    Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.